Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
Azra Raza(University of Illinois Chicago), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Deborah Mulford(University of Rochester), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Naomi Galili(Columbia University Irving Medical Center), David P. Steensma(Harvard University), Scott E. Smith(Loyola University Medical Center), Gail L. Brown(Palo Alto Institute), Roger M. Lyons(Hematology Oncology Associates), Ralph V. Boccia(Center for Cancer and Blood Disorders), Mikkael A. Sekeres(University of Miami)
Cited by 27
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k